Lineage Cell Therapeutics (LCTX) Tops Q4 EPS by 2c
Tweet
Share
E-mailGet Alerts LCTX Hot Sheet
Join SI Premium – FREE
Lineage Cell Therapeutics (NYSE: LCTX) reported Q4 EPS of $0.02. Revenue for the quarter came in at $2.9 million.
For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Rockstar Energy founder seeks CEO role at Celsius Holdings
- Soligenix, Inc. (SNGX) Tops Q2 EPS by 8c
- Lineage Cell Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
